Despite fears of high costs, employers did not face a surge in human immunodeficiency virus (HIV)-related claims. Innovative company strategies are emerging as treatments improve patient outlooks and raise expenses.
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: